Scribd Logo
Upload

Welcome to Scribd!

  • Swot Analysis of Telmisartan

    Uploaded by

    Ishan_Vyas
    194 views2 pages
    This document presents a SWOT analysis for a new pharmaceutical company. The strengths include an existing customer base and new pulsatile release technology that reduces side effects. Weaknesses are high production costs and lack of brand recognition as a new company. Opportunities exist in the growing market for the molecule and shift to disease patterns. Threats include strong competition from established brands of the same molecule and other molecules from large pharmaceutical companies. The document also includes a projected sales graph showing anticipated growth.

    Original Description:

    Original Title

    SWOT ANALYSIS OF TELMISARTAN

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document presents a SWOT analysis for a new pharmaceutical company. The strengths include an existing customer base and new pulsatile release technology that reduces side effects. Weaknesses are high production costs and lack of brand recognition as a new company. Opportunities exist in the growing market for the molecule and shift to disease patterns. Threats include strong competition from established brands of the same molecule and other molecules from large pharmaceutical companies. The document also includes a projected sales graph showing anticipated growth.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    194 views2 pages

    Swot Analysis of Telmisartan

    Uploaded by

    Ishan_Vyas
    This document presents a SWOT analysis for a new pharmaceutical company. The strengths include an existing customer base and new pulsatile release technology that reduces side effects. Weaknesses are high production costs and lack of brand recognition as a new company. Opportunities exist in the growing market for the molecule and shift to disease patterns. Threats include strong competition from established brands of the same molecule and other molecules from large pharmaceutical companies. The document also includes a projected sales graph showing anticipated growth.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    SWOT ANALYSIS

    STRENGTHS WEAKNESS
    EXISTING CUSTOMER BASE
    HIGH PRODUCTION COST
    ADDED ADVANTAGE OF
    CYCLODEXTRIN NEW COMPANY SO NOT KNOWN
    NEW TECHNOLOGY - PULSATILE IN THE MARKET
    RELEASE
    REDUCTION IN SIDE EFFECTS

    OPPORTUNITIES THREATS
    MOLECULE IN THE GROWTH TOO MANY TELMISARTAN BRANDS IN
    THE MARKET
    STAGE OF THE PLC
    COMPETION FROM OTHER
    TOTAL MAKET SIZE 396 cr – MOLECULES SPECIALLY OLMESARTAN
    GROWING AT 47% STRONG HOLD OF GLENMARK, CIPLA,
    SHIFT IN DISEASE PATTERN LUPIN, DR REDDY’S IN THE MARKET
    Projected Sales(CR)
    8

    5
    Projected Sales(CR)
    4

    0
    2010.5 2011 2011.5 2012 2012.5 2013 2013.5 2014 2014.5

    You might also like